Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Millipore Corporation and Novozymes Form Strategic Alliance to Supply Animal-Free Cell Culture Supplements for Bioprocessing

Published: Tuesday, December 18, 2007
Last Updated: Tuesday, December 18, 2007
Bookmark and Share
Alliance will accelerate launch of new animal-free supplements and provide customers with a source of high performance cell culture products.

Millipore Corporation and Novozymes have announced an agreement to develop, market, and sell new, animal-free cell culture supplements for biopharmaceutical manufacturing.

The new products, to be marketed under the brand name CellPrime™, will be manufactured by Novozymes and sold through Millipore’s sales organization. The alliance expands the existing relationship between Millipore and Novozymes and will initially focus on developing recombinant human albumin and recombinant human transferrin.

Cell culture supplements help mammalian cells produce the proteins that form the basis of biologic drugs. Today, customers seeking to utilize defined, animal-free supplements in their biopharmaceutical production processes have limited options. The CellPrime™ products are designed to reduce risk and ease regulatory concerns for biopharmaceutical manufacturers. Additionally, these products will help to improve the consistency and productivity of customers’ industrial cell culture processes.

“Our expanded relationship with Novozymes broadens our commitment to develop a portfolio of high quality, animal-free alternatives that optimize productivity, address drug safety, and ease regulatory approval,” said Andrew Bulpin, Ph.D., Vice President of Millipore’s Upstream Bioprocessing Business Unit.

“Our CellPrime™ products will give customers a reliable, long-term supply of regulatory compliant supplements and address their desire to eliminate the use of animal-derived products in their manufacturing processes,” Mr. Bulpin continued.

“We are excited about expanding our relationship with Millipore given the company’s leading position in serving the biopharmaceutical manufacturing market,” said Peter Rosholm, Vice President of Novozymes Biopharma.

“By leveraging the strengths of both companies, we will accelerate the introduction and adoption of innovative new products and enable our customers’ to re-think their production processes. This collaboration further strengthens our position as a strategic partner for biopharmaceutical companies and broadens Novozymes’ biopharmaceutical product portfolio.”

The process of manufacturing biologic drugs such as monoclonal antibodies begins with growing mammalian cells in a bioreactor. These cells are cultured in media and require the addition of supplements to enable efficient production of therapeutic proteins that form the basis of biologic drugs.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cellular Reprogramming – What the Future Holds
Advancements in cellular reprogramming are coming at a furious pace. Along with these scientific breakthroughs come new opportunities for the development of therapeutics, disease modeling, drug screening, and new pathways to personalized medicine.
Friday, July 23, 2010
Millipore Opens new Bioprocess Manufacturing Facility in Massachusetts
New facility will produce company’s Mobius® single-use product line used for biopharmaceutical manufacturing technologies.
Wednesday, June 10, 2009
Millipore Extends Exclusive License Agreement with University of Dundee
The ongoing collaboration will bring novel cell signaling tools and services to life science researchers worldwide.
Friday, October 10, 2008
ReNcell® VM Neural Stem Cell Line Models Parkinson’s Disease
Milipore announces the publication of a new discovery derived from its ReNcell VM neural stem cell line.
Tuesday, July 22, 2008
Millipore Launches Progenitor Cell-Enriched Primary Human Epithelial Cell Cultures
According to Company, these primary cell cultures are designed to provide an enriched population of progenitor cells from skin, cornea, and bladder epithelia.
Friday, April 18, 2008
Millipore Announces Stem Cell Tested Initiative
Millipore’s Stericup with Express PLUS membrane is the first available under this initiative.
Wednesday, December 05, 2007
Millipore Corporation Announces new ReNcell® Data from Collaboration with ReNeuron
Millipore releases new data concerning its ReNcell neural stem cell lines at the ISSCR meeting in Cairns, Australia on June 20, 2007.
Thursday, June 21, 2007
Scientific News
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Stem Cells Rescue Patients from Mitochondrial Disease
A study led by OHSU researchers has revealed a critical first step in developing a new gene and stem cell regenerative technique for treating patients with mitochondrial disease.
Eco-Friendly Nanobullet to Battle Bacteria
Researchers have developed a method to combat bacteria by engineering nanoscale particles that add the antimicrobial potency of silver to a core of lignin, a ubiquitous substance found in all plant cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!